ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,114.63
      -0.01%
      US Tech 100
      21,524.40
      0.41%
      Dow Jones
      44,546.08
      -0.37%
      Brent Oil
      75.205
      0.09%
      Bitcoin
      95,975.22
      0.21%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Omeros Corporation (OMER) Quote

      Omeros Corporation

      Omeros Corporation (OMER)

      Omer Spa
      9.18
      0.06
      (0.66%)
      Closed February 18 4:00PM
      Delayed by 15 minutes
      9.14
      -0.04
      (-0.44%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      9.18
      Bid
      9.10
      Ask
      9.42
      Volume
      425,140
      9.0825 Day's Range 9.43
      2.612 52 Week Range 13.60
      Market Cap
      531.979M
      Previous Close
      9.12
      Open
      9.15
      Last Trade
      10
      @
      9.1
      Last Trade Time
      Financial Volume
      $ 3,925,232
      VWAP
      9.2328
      Average Volume (3m)
      931,105
      Shares Outstanding
      57,949,760
      Dividend Yield
      -
      PE Ratio
      -4.51
      Earnings Per Share (EPS)
      -2.03
      Revenue
      -
      Net Profit
      -117.81M

      About Omeros Corporation

      Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injec... Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.omeros.com
      Headquarters
      Tumwater, Washington, USA
      Founded
      -
      Omeros Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OMER. The last closing price for Omeros was $9.12. Over the last year, Omeros shares have traded in a share price range of $ 2.612 to $ 13.60.

      Omeros currently has 57,949,760 shares outstanding. The market capitalization of Omeros is $528.50 million. Omeros has a price to earnings ratio (PE ratio) of -4.51.

      Ask ADVFN Intelligence (AI)

      OMER Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 16 2025
      OMER (0.66%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 19 2024
      OMER (0.66%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 13 2024
      OMER (0.66%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.11.10132158599.089.1958.254128018.74071003CS
      4009.189.70948.164207118.88051217CS
      121.4819.22077922087.713.67.293110510.11905494CS
      265.08123.9024390244.113.63.546938578.26245217CS
      525.44145.4545454553.7413.62.6125531096.71837041CS
      1562.9146.41148325366.2713.60.926948144.62945769CS
      260-3.44-27.258320126812.6225.490.927731408.46892251CS

      OMER - Frequently Asked Questions (FAQ)

      What is the current Omeros share price?
      The current share price of Omeros is $ 9.18
      How many Omeros shares are in issue?
      Omeros has 57,949,760 shares in issue
      What is the market cap of Omeros?
      The market capitalisation of Omeros is USD 528.5M
      What is the 1 year trading range for Omeros share price?
      Omeros has traded in the range of $ 2.612 to $ 13.60 during the past year
      What is the PE ratio of Omeros?
      The price to earnings ratio of Omeros is -4.51
      What is the reporting currency for Omeros?
      Omeros reports financial results in USD
      What is the latest annual profit for Omeros?
      The latest annual profit of Omeros is USD -117.81M
      What is the registered address of Omeros?
      The registered address for Omeros is 3400 CAPITOL BLVD SE, TUMWATER, WASHINGTON, 98501
      What is the Omeros website address?
      The website address for Omeros is www.omeros.com
      Which industry sector does Omeros operate in?
      Omeros operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      JTAIJet AI Inc
      $ 6.02
      (133.33%)
      		101.64M
      SRMSRM Entertainment Inc
      $ 0.6999
      (95.50%)
      		248.48M
      WRDWeRide Inc
      $ 31.4877
      (83.39%)
      		20.57M
      INLFINLIF Limited
      $ 16.27
      (80.58%)
      		7.67M
      MBRXMoleculin Biotech Inc
      $ 2.1201
      (66.94%)
      		134.88M
      BLACBellevue Life Sciences Acquisition Corporation
      $ 3.08
      (-56.31%)
      		430.77k
      BLACUBellevue Life Sciences Acquisition Corporation
      $ 3.36
      (-52.68%)
      		5.21k
      CSAICloudastructure Inc
      $ 19.0001
      (-49.58%)
      		1.03M
      NEXNNexxen International Ltd
      $ 10.30
      (-49.16%)
      		164.82k
      BSLKBolt Projects Holdings Inc
      $ 0.6626
      (-46.13%)
      		13.4M
      CNSPCNS Pharmaceuticals Inc
      $ 0.1415
      (31.26%)
      		489.28M
      MGOLMGO Global Inc
      $ 0.7176
      (-15.08%)
      		417.31M
      SRMSRM Entertainment Inc
      $ 0.6999
      (95.50%)
      		254.39M
      INTCIntel Corporation
      $ 23.60
      (-2.20%)
      		230.26M
      NVDANVIDIA Corporation
      $ 138.85
      (2.63%)
      		194.99M

      OMER Discussion

      View Posts
      glenn1919 glenn1919 3 months ago
      omer................................nice miss.................................
      👍️0
      TrendTrade2016 TrendTrade2016 3 months ago
      OMER MONSTER PLAY OF THE DAY
      👍️0
      Monksdream Monksdream 1 year ago
      OMER new 52=week low
      Then bounce
      👍️0
      shurtha2000 shurtha2000 1 year ago
      $341M cash and $12M recievables
      👍️0
      starkd748 starkd748 2 years ago
      Gap filled 6s 7s next top
      👍️0
      Roadtojourney Roadtojourney 2 years ago
      With the type of news this should have been above 5 not sure whats wrong here?
      👍️0
      starkd748 starkd748 2 years ago
      3.20 gap must fill now
      👍️0
      TheFinalCD TheFinalCD 2 years ago
      OMER $200M PAYMENT
      👍️0
      makinezmoney makinezmoney 2 years ago
      $OMER: She back on fire now............ sheeeshhhhhhhhhhhhhh


      Go baby goooooooooo.......... $3 breaker upside




      GO $OMER
      👍️0
      starkd748 starkd748 2 years ago
      Weeeeeeee
      👍️0
      starkd748 starkd748 2 years ago
      We get some 5s I'm backing up the truck
      👍️0
      starkd748 starkd748 2 years ago
      Was a good trade but it's been done since 7s
      👍️0
      starkd748 starkd748 3 years ago
      Weeeeee
      👍️0
      starkd748 starkd748 3 years ago
      Weeeeeeeeeeeee
      👍️0
      starkd748 starkd748 3 years ago
      Yesss
      👍️0
      starkd748 starkd748 3 years ago
      Looking good
      👍️0
      starkd748 starkd748 3 years ago
      Weeeeee
      👍️0
      starkd748 starkd748 3 years ago
      Yesss
      👍️0
      starkd748 starkd748 3 years ago
      Bounced off the low 3s time to load
      👍️0
      starkd748 starkd748 3 years ago
      Maybe an A B C ... 2.17 might coming
      👍️0
      starkd748 starkd748 3 years ago
      Not ready yet
      👍️0
      starkd748 starkd748 3 years ago
      I like this at a certain fib level hehehe
      👍️0
      bandit007 bandit007 3 years ago
      Great day here! $OMER
      👍️0
      bandit007 bandit007 3 years ago
      Breaking out!
      👍️0
      bandit007 bandit007 3 years ago
      Looking good here. Steady climb
      👍️0
      bandit007 bandit007 3 years ago
      Looking good here. Steady climb
      👍️0
      Scott 75 Scott 75 3 years ago
      Wow! Thanks for sharing. I can't believe with all that going for it and the price is so beaten down.
      👍️0
      Nefyn Nefyn 3 years ago
      So what happens to OMER…a public company with tons of cash and no business operations?
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      Bahhh Bahhh

      gonna do this all day long
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      another round for the apes Lets GO !!
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      Glad I'm just a robot no emotions needed
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      Fk with BB My new addiction
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      IN now I'm gonna tick flip this POS to death
      👍️0
      JackAskSlap JackAskSlap 3 years ago
      Trying for the baseline
      no holds barred..
      👍️0
      Jess070283 Jess070283 3 years ago
      Load it up!$$$
      👍️0
      TheGreenReaper TheGreenReaper 3 years ago
      OMER$$$$
      👍️0
      Golden Cross Golden Cross 3 years ago
      $14 Targeting
      👍️0
      crudeoil24 crudeoil24 3 years ago
      59M trading float. Huge news out >
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Shorts feeling the heat!!!!! >
      👍️0
      crudeoil24 crudeoil24 3 years ago
      >>>>> GANGBUSTERS <<<<< $$$$$

      OMER
      👍️0
      crudeoil24 crudeoil24 3 years ago
      OMER > That is a sweet revenue deal. OMER heading to $20.00+
      $125 million upfront payment and $200 million on achievement of commercial milestone
      Royalties of 50% on U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million milestone, after which royalties adjust to 30% of U.S. net sales
      Royalties of 15% on ex-U.S. net sales
      OMIDRIA to become a premier product in Rayner’s ophthalmology franchise
      In addition to acquiring the OMIDRIA commercial organization, including the current OMIDRIA sales force, Rayner plans to further expand its U.S. and ex-U.S. sales forces
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      https://ih.advfn.com/stock-market/NASDAQ/omeros-OMER/stock-news/86711139/omeros-announces-agreement-to-sell-omidria-franch
      👍️0
      Frankestin Frankestin 3 years ago
      Here are the 5!
      Very interesting if it goes under!
      I would be tempted to open the position now!
      👍️0
      Frankestin Frankestin 3 years ago
      Someone says 5 ... will it get there?
      I would like to enter but of course they spend a lot on research and development... and for sell
      👍️0
      Frankestin Frankestin 3 years ago
      ooOOoo
      I take a handful these days!
      👍️0
      Termite7 Termite7 3 years ago
      Buying opportunity???
      👍️0
      frugalNorwegian frugalNorwegian 4 years ago
      I created a page on my site talking about OMER. Let me know if I am missing any nuggets. Thanks.

      https://frugalnorwegian.com/omer

      Summary: This company is a prime candidate for a buyout if FDA approval is given.
      👍️0
      Dr_Thorfin Dr_Thorfin 4 years ago
      If one is worried about fda's delay, Check out @alanrobertross message on StockTwits http://stocktwits.com/alanrobertross/message/333077805
      👍️0
      umiak umiak 4 years ago
      Tute ownership up to 78% been hovering around 50% for years. 20% short
      👍️0
      umiak umiak 4 years ago
      Not new news but I like the smart reporting style:
      Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

      1/19/21, 8:06 AM
      10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

      Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

      The FDA has set the Prescription Drug User Fee Act action date on July 17.
      👍️0

      Your Recent History

      NASDAQ
      OMER
      Omeros
      NASDAQ
      FFIE
      Faraday Future Intellige...
      BIT
      1GILD
      Gilead Sciences
      COIN
      SNXGBP
      Synthetix Network Token
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads